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Abstract
Background: Grb2-associated binder 2 (Gab2), a scaffolding adaptor protein, has recently been implicated in cancer
progression. However, the role of Gab2 in the progression and metastasis of colorectal cancer (CRC) remains unclear.
Methods: Gab2 expression was assessed in CRC patient specimens as well as in CRC cell lines. Recombinant lentivirus
vector containing Gab2 gene and its small interfering RNAs were constructed and introduced into CRC cells.
Cell migration and invasion ability were evaluated by transwell assays in vitro, and in vivo metastasis was performed
on nude mice model. Moreover, the expression of Gab2 and epithelial-to-mesenchymal transition (EMT)-associated
proteins (E-cadherin and vimentin) were assessed by western blot and qRT-PCR in CRC cells to evaluate the correlation
between Gab2 and EMT. Finally, we evaluated the impact of Gab2 on the activation of its downstream signaling
effectors, and furthermore the effects of these pathways on Gab2 induced-EMT were also detected.
Results: We confirmed that increased Gab2 expression correlated with higher tumor node metastasis stage and highly
invasive CRC cell lines. Ectopic expression of Gab2 promoted metastasis of CRC cells, whereas silencing of Gab2
resulted in inhibited metastasis both in vitro and in vivo. Overexpression of Gab2 in CRC cells induced EMT,
whereas knockdown of Gab2 had the opposite effect. Furthermore, upregulation of Gab2 expression obviously
stimulated the activation of extracellular signal-regulated kinase-1/2 (ERK1/2), and increased the expression of
matrix metalloproteinase-7 (MMP7) and matrix metalloproteinase-9 (MMP9) in CRC cells. Conversely, downregulation of
Gab2 expression significantly decreased the activation of ERK1/2, and inhibited MMP7 and MMP9 expression. U0126, an
inhibitor of mitogen-activated protein kinase (MEK), can reverse the effects of Gab2 on EMT.
Conclusions: Our work highlights that Gab2 induces EMT through the MEK/ERK/MMP pathway, which in turn
promotes intestinal tumor metastasis.
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Background
Colorectal cancer (CRC) is the third most commonly car-
cinomas in males and the second in females throughout
the world, with an estimated 1.4 million new cancer cases
and nearly 0.7 million deaths each year [1]. The CRC inci-
dence in the People’s Republic of China has been increas-
ing annually and it will continue to rise in the next years
[2]. Although the survival rate for patients with CRC has
increased at early stages, as a result of improved detection
and increased awareness, the long-term survival rate still
remains very poor, mainly due to local recurrence and dis-
tant metastases formation [3, 4]. Metastasis, one of the
six initial cancer hallmarks [5], which is a main reason
of CRC-associated survival rate depressed [6]. Approxi-
mately 35 % of patients with CRC have metastatic dis-
ease at diagnosis and more than one-third of patients
will ultimately develop metastatic disease, however, the
exact molecular mechanism underlying CRC metastasis
is little known [7–9]. Improving understanding the key
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molecules in these processes, may provide novel insight
for designing effective anti-cancer therapies.
Grb2-associated binder 2 (Gab2), a member of the DOS/
Gab family of scaffolding adapters, has been reported to
play important roles in the progression and metastasis of
human cancers, particularly in breast and ovarian cancers
and melanoma [10]. Although Gab2 has a modest impact
on mammary tumor initiation/growth, Gab2 deletion leads
to impaired ERK activity and attenuated mammary tumor
metastasis [11]. Gab2 triggers epithelial-to-mesenchymal
transition (EMT) and promotes the migration and invasion
of ovarian cancer cells through activation of the phos-
phatidylinositol 3-kinase (PI3K) pathway [12]. In melan-
oma, Gab2 expression promotes the migration, invasion
and metastasis of tumor cells via activation of the PI3K/
AKT signaling [13]. These data indicates that Gab2 and
Gab2-mediated signaling pathways are involved in the me-
tastasis of human tumor cells.
However, whether Gab2 has any role in the metastasis of
CRC and its underlying mechanism remains unknown. In
this study, the effects of Gab2 on CRC metastasis as well as
its relative molecular mechanism were investigated using in
vitro CRC cell lines and in vivo mouse model systems. We
demonstrate that Gab2 induces EMT by the MEK/ERK/
MMP pathway, which in turn promotes CRC cells metasta-
sis. The current findings suggest that Gab2 plays a vital role
in regulating CRC metastasis and may serve as a potential
target for diagnosis and therapy in CRC.
Methods
Tissue samples
Samples from 35 CRC patients who had undergone proc-
tocolectomy with lymph node (LN) dissection for CRC at
the Department of gastrointestinal Surgery, the First Affili-
ated Hospital of Zunyi Medical College (Zun’yi, China)
between May 2015 and July 2015 were included in the
study. Patients did not receive neoadjuvant therapy. After
surgical resection, the resected specimens were histologi-
cally examined by hematoxylin and eosin (HE)-staining
and were immediately put into liquid nitrogen until fur-
ther use. Total RNA from the frozen tissues was isolated
with Trizol (Invitrogen, USA) according to the manufac-
turer’s instructions. All patients provided written informed
consent before surgery, and our study were approved by
the Ethics Committee of the First Affiliated Hospital of
Zunyi Medical College according to the 1975 Declaration
of Helsinki.
Cell lines and culture conditions
The human CRC cell lines HT29, SW480, SW620 and
LOVO, and a normal human intestinal epithelial cell line
FHC were obtained from the American Type Culture Col-
lection (ATCC, Manassas, USA), and authenticated accord-
ing to the ATCC recommendations. SW480 and SW620
cells were cultured in Leibovitz’s L-15 medium (GIBCO La-
boratories, Grand Island, NY, USA) supplemented with
10 % fetal bovine serum (FBS) (HyClone, Logan, UT, USA),
100 U/ml penicillin and 100 μg/ml streptomycin. HT29
cells were cultured in McCoy’s medium (GIBCO) supple-
mented with 10 % FBS and antibiotics. LOVO and FHC
were maintained in RPMI-1640 medium (HyClone) supple-
mented with 10 % FBS and antibiotics. All the cells were
cultured at 37 °C in a humidified incubator of 5 % CO2.
RNA extraction and real-time PCR
Total RNA was extracted using Trizol (Invitrogen,
USA) according to the manufacturer’s instructions. The
obtained RNA was first reversely transcribed into
cDNA by using RT reagent Kit (TakaRa, Japan). Quan-
titative reverse transcription-PCR (qRT-PCR) analysis
was performed as previously described [14]. The se-
quences of primers in this section are the followings:
(1) Gab2: 5′-GTGGGGGATCTGAATGTTTTTATG-3′
(forward) and 5′-GCCCCAGGGTAGAATGAAACG-3′
(reverse); (2) E-cadherin: 5′-GCTCGGCCTGAAGTG
ACTCG-3′ (forward) and 5′-CCGCTTCCTTCATAG
TCAAACAC-3′ (reverse); (3) Vimentin: 5′-CCAGGC
AAAGCAGGAGTCCAC-3′ (forward) and 5′-GCTT
CCTGTAGGTGGCAATCTC-3′ (reverse); (4) GAPDH:
5′-GAAGGTGAAGGTCGGAGTC-3′ (forward) and
5′-GAAGATGGTGATGGGATTTC-3′ (reverse). GAP
DH was used as an internal control.
Western blot analysis
Western blot analysis was performed as previously de-
scribed [14]. The following commercial antibodies were
used in this study: Gab2 (OriGene Technologies, USA),
E-cadherin, vimentin, MMP7 and MMP9 (Abcam, UK),
phospho-AKT, total AKT, phospho-ERK1/2 and total
ERK1/2 (Invitrogen, USA), GAPDH and β-actin (Immun-
ology Consultants Laboratory, USA).
Immunohistochemical staining
Immunohistochemical assay was performed on
paraformaldehyde-fixed paraffin sections as previous
reported [14]. The Gab2 (OriGene Technologies, USA)
primary antibody was used at a 1:150 dilution in the im-
munohistochemistry assays. The immunostaining intensity
and average percentage of positive cells were evaluated as
previous reported [14]. According to the chromatosis in-
tensity, no staining, light yellow, buffy and brown are
scored 0, 1, 2, and 3, respectively. And the percentage of
positive cells was categorized as the following grades: 0
(less than 5 %), 1 (5–25 %), 2 (26–50 %), and 3 (>51 %) ac-
cordingly. By multiplying the staining intensity and the
percentage of positive cells, the final weighed expression
score was ranged from 0 to 9. The sum of the staining in-
tensity score and the percentage score was used to define
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the Gab2 protein expression levels: 0–2, low expression
and 3–9, high expression.
Lentivirus production and construct design
Retroviral expression vector CMV-puro and CMV-puro
containing Gab2 gene were designed and provided by
Cyagen Biosciences Inc. (Guangzhou, China). On the basis
of the Gab2 sequence, one short hairpin RNA was de-
signed using the small interfering RNAs (siRNAs) Target
Finder (InvivoGene, San Diego, CA, USA). The effect-
ive Gab2 siRNA sequence is 5′- GCACCAATTCTG
AAGACAA -3′, and the control-siRNA sequence is
5′-TTCTCCGAACGTGTCACGT-3′. Lentiviral vectors
encoding siRNAs and the control-siRNA sequence were
designed and provided by Genechem lnc. (Shanghai,
China).
Migration and invasion assay
Migration and invasion assays were using Transwell sys-
tem (24-well, 8 μm pore size with polycarbonate mem-
brane; Corning Costar, Lowell, MA, USA). Six hundred
microlitres of the medium with 15 % FBS was added to
the lower well of each chamber and 5 × 104 cells/well re-
suspended in 200 μl serum-free medium were added to
the upper inserts. After 48 h incubation, the cells that
had migrated through the filter into the lower wells were
stained with 0.1 % crystal violet and counted using fluor-
escence microscopy. The invasion assay was performed in
the same way as the migration assay except that the mem-
brane was coated with Matrigel (BD Biosciences, SanJose,
CA, USA). Three independent experiments were per-
formed with triplicate wells. DMSO (vehicle) or U0126
was added to both the top and bottom of transwell.
In vivo metastasis development assay
To produce experimental lung and liver metastasis,
SW480-NC, SW480-Gab2, SW620-si-Ctrl and SW620-
Gab2si cells (1 × 106 cells) were injected into the lateral
tail veins of 5–6 weeks-old BALB/c nu/nu female mice
(six mice per group). After 4 weeks, all the mice were
killed under anesthesia. The lungs and livers were col-
lected and fixed in 10 % formalin. For tissue morphology
evaluation, HE-staining was performed on sections from
embedded samples. All animal experiments were per-
formed with the approval of Zunyi Medical College Ani-
mal Care and Use Committee.
Statistical analysis
All values were represented as the mean ± SEM from at
least three independent experiments. Pearson’s χ2-test was
used for clinical correlative studies. Student’s t-test for two
groups or one-way analysis of variance (ANOVA) for
Fig. 1 Gab2 is significantly upregulated in LN metastasis-positive CRC tissues. a Immunohistochemistry analysis of Gab2 expression in 35 paired
CRC tissues. b Results of immunohistochemical staining were evaluated by the staining scores. *P < 0.05 vs non-metastatic CRC or normal tissues.
#P < 0.05 vs normal tissues. c qRT-PCR analysis of Gab2 expression in human CRC primary tumors, LN-positive (n = 9) or -negative (n = 9). Matching
normal colorectal tissue sample from the same patient was used for normalization
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three or more groups were performed to evaluate the stat-
istical significance. Differences were considered significant
at P values less than 0.05.
Results
Gab2 is significantly upregulated in LN metastasis-positive
CRC tissues
Our previous study has shown that Gab2 is overexpressed
in CRC tissues, and this overexpression is significantly
correlated with lymph node (LN) metastasis [14]. In this
study, we also assessed Gab2 expression in a tissue
microarray of 35 CRC patients (Additional file 1: Table
S1). The results of immunohistochemical staining showed
that Gab2 was significantly upregulated in primary sites of
metastatic CRC compared with either non-metastatic
CRC or normal tissues (Fig. 1a, b). To investigate the cor-
relation between Gab2 overexpression and CRC metastasis,
we detected Gab2 expression in 9 pairs of LN metastasis-
positive (LN-positive group) and LN metastasis-negative
(LN-negative group) primary CRC specimens. Real-time
PCR analysis showed that Gab2 mRNA level was obviously
higher in the LN-positive group than in the LN-negative
Fig. 2 Gab2 promotes CRC cells migration and invasion in vitro. a Expression of Gab2 in four human CRC cell lines relative to the normal human
intestinal epithelial cell line FHC was detected by qRT-PCR. b Western blot analysis of Gab2 expression in different CRC cell lines. c Migration and
invasion assay of SW480-NC and SW480-Gab2 cells. d Migration and invasion of SW480-NC and SW480-Gab2 cells were quantitatively analyzed.
Columns are the average of three independent experiments ± SEM. e and f Migration and invasion assay of SW620-si-Ctrl and SW620-Gab2si cells
(two clones, c and d). ***P < 0.001
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group (Fig. 1c). Taken together, these results suggest that
the expression of Gab2 is positively correlated with the me-
tastasis of CRC.
Gab2 accelerates CRC cell migration and invasion in vitro
To determine whether Gab2 expression associates with
the metastatic potential of CRC cells, we detected the ex-
pression of Gab2 in four human CRC cell lines (HT29,
SW480, SW620 and LOVO) and in a normal human in-
testinal epithelial cell line FHC. The levels of Gab2 expres-
sion were obviously increased in SW620 and LOVO cells,
which have highly metastatic abilities, compared with ei-
ther the poorly metastatic cell lines HT29 and SW480 or
the normal human intestinal epithelial cell line FHC
(Fig. 2a, b). Considered that SW480 and SW620 cells were
isolated from a same patient [15], these cells therefore
have the same genetic background but different metastatic
potential [16].
To explore whether Gab2 affects the metastatic pheno-
type of CRC cells, SW480 cells were infected with lentiviral
vectors containing Gab2 gene or a control lentivirus and
stable clones were established (SW480-Gab2 and SW480-
NC, respectively). Gab2-specific small interfering RNAs
(siRNAs) or its corresponding control siRNA were intro-
duced into SW620 cells and stable clones were established
(SW620-Gab2si and SW620-si-Ctrl, respectively). In order
to determine the generality of the impact of Gab2 regula-
tion in cell metastasis, we adopted transwell assays. As
results, upregulation of Gab2 expression in SW480 cells
significantly enhanced cell migration and invasion (Fig. 2c,
d). Conversely, downregulation of Gab2 in SW620 cells
markedly reduced cell migration and invasion (Fig. 2e, f ).
These data indicates that Gab2 promotes metastasis of
CRC cells in culture.
Gab2 induces metastasis in a xenograft model
Next, we studied the effect of Gab2 on tumor metastasis in
vivo. SW480-NC, SW480-Gab2, SW620-si-Ctrl and
SW620-Gab2si cells were transplanted into the nude mice
via tail vein injection. After 4 weeks, mice were anesthe-
tized, and their lungs and livers were dissected and HE-
staining was performed to evaluate tissue morphology.
Histologic analyses confirmed that the incidence of lung
and liver metastases was obviously enhanced in mice
injected with SW480-Gab2 cells and significantly decreased
in mice injected with SW620-Gab2si cells, compared with
the corresponding control groups (Fig. 3a). Two out
of six mice injected with SW480-NC cells had small
lung metastatic nodules, whereas four out of six mice
in the SW480-Gab2 group ended up with heavy lung
Fig. 3 Gab2 enhances CRC cells metastasis in a xenograft model. a Images showing representative HE-staining of lungs and livers isolated from
mice that received tail vein injection of SW480-NC, SW480-Gab2, SW620-si-Ctrl and SW620-Gab2si cells. Each group contains six mice. b The numbers
of pulmonary and liver metastatic nodules were counted and analyzed with Student’s t-test
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metastasis. Conversely, silencing of Gab2 expression in
SW620 cells had small lung metastatic nodules when
compared with the control group. Moreover, the counts of
lung and liver metastatic nodules exhibited significantly
increased in the SW480-Gab2 group and significantly de-
creased in SW620-Gab2si group, compared with the cor-
responding control groups (Fig. 3b). These results suggest
that Gab2 can enhance CRC cells metastasis in vivo.
Gab2 regulates EMT in CRC cell
The EMT is a powerful process in tumor invasion and
metastasis. During the EMT process, the molecular repro-
gramming and phenotypic changes characterized by a
transition from polarized immotile epithelial cells to mo-
tile mesenchymal cells, thus leading to increased motility
and invasion [17]. Moreover, the transition is character-
ized by a decrease in the expression of epithelial markers
(such as E-cadherin) as well as an increase in the expres-
sion of mesenchymal markers (such as vimentin) [18, 19].
By comparing the morphology of the cell models de-
scribed above under a light microscope, we found that ele-
vated expression of Gab2 in SW480 cells induced the
conversion of polarized epithelial cells to spindle-shaped,
fibroblast-like mesenchymal cells with decreased cell-cell
contact. Conversely, silencing of Gab2 in SW620 cells
exhibited an increase in cell-cell adhesion and an epitheli-
oid morphology (Fig. 4a). To confirm that Gab2 induced
EMT to promote CRC metastasis, we assessed the expres-
sion of EMT-markers in these cell models. As results, a de-
crease in the expression of E-cadherin and an increase in
the expression of vimentin were observed in SW480-Gab2
cells, compared with the control cells (Fig. 4b, c). By con-
trast, a marked decrease in the expression of vimentin and
a significant increase in the expression of E-cadherin were
observed in SW620-Gab2si cells, compared with the con-
trol cells (Fig. 4b, d). These results suggest that Gab2 is
critical for the acquisition of EMT characteristics and may
contribute to the EMT-induced invasive phenotype in
CRC cells.
Gab2 positively regulates ERK signaling in CRC cell
Recent studies have shown that the expression of several
MMPs was enhanced in many types of cancer [20–22]. In
these MMPs, it has been demonstrated that MMP7 and
MMP9 were involved in the progression and metastasis of
CRC [23–25]. To investigate the possible mechanism of
Gab2 participating in cell metastasis of colorectal carcin-
oma, we examined its downstream effectors, AKT and
ERK. Overexpression of Gab2 in SW480 cells significantly
increased phosphorylation of ERK1/2, whereas knockdown
Fig. 4 Gab2 regulates EMT in CRC cells. a Morphological changes by Gab2 in SW480 and SW620 cells. b, c and d Western blot and qRT-PCR show
downregulated expression of E-cadherin and upregulated expression of vimentin in SW480-Gab2 cells. In contrast, silencing of Gab2 resulted in
increased expression of E-cadherin and decreased expression of vimentin in SW620-Gab2si cells. *P < 0.05
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of Gab2 in SW620 cells obviously reduced the activation
of ERK1/2 (Fig. 5). Not as expected, the phosphorylation of
AKT did not show marked increased or decreased in these
cells (Fig. 5). Moreover, we also detected the expression of
MMP7 and MMP9 in these cells, and found that increased
MMP7 and MMP9 expression in SW480-Gab2 cells com-
pared with the control cells, and decreased MMP7 and
MMP9 expression in SW620-Gab2si cells compared with
the control cells (Fig. 5). These data indicates that Gab2
may enhance CRC cells metastasis through the ERK/MMP
pathway.
Pharmacological inhibitor of MEK inhibits Gab2-induced EMT
To test the hypothesis that the commissioning of EMT by
Gab2 is required for the activation of MEK/ERK signaling
in colorectal carcinoma, we explore whether U0126, an
effective MEK inhibitor, can inhibit Gab2-induced EMT
and cell migration and invasion in CRC. Western blot ana-
lyses confirmed that the expression of E-cadherin was par-
tially restored and the expression of vimentin, MMP7 and
MMP9 was reduced upon using U0126 in SW480-Gab2
cells (Fig. 6a). Accordingly, migration and invasion of
SW480-Gab2 cells were analyzed in the absence or pres-
ence of U0126 using transwell migration and invasion as-
says. As results, migration and invasion of SW480-Gab2
cells were significantly reduced in the presence of U0126
(Fig. 6b, c). These data indicates that Gab2-induced EMT
and cell metastasis is dependent on MEK/ERK/MMP sig-
naling in CRC.
Discussion
It has been widely recognized that MEK/ERK signaling is
participated in the progression and metastasis of CRC
[26–28]. In addition, expression of a constitutively active
mutant of MEK1 or MEK2 in rodent normal intestinal
epithelial cells (IECs) is sufficient to induce growth, EMT
and formation of invasive metastatic tumors in nude mice
[29, 30]. In this study, we have shown that Gab2 promotes
cell migration and invasion of CRC through activation of
the MEK/ERK pathway, further showing the importance
of ERK signaling for CRC metastasis. Additionally, we
provide evidence supporting the involvement of Gab2 in
the regulation of EMT in cancer.
Gab2 has recently been proposed to be a critical mol-
ecule in the regulation of cancer metastasis [10], although
the exact mechanism of Gab2 in metastasis remains un-
clear. We found that overexpression of Gab2 enhanced
CRC cell migration and invasive properties. Conversely,
knockdown of Gab2 had the opposite effect. In accord-
ance with our study, Gab2 was reported to be one of the
Fig. 5 Gab2 expression regulates ERK signaling and increases MMP7 and MMP9 expression in CRC cells. a Gab2 overexpression enhances MMP7
and MMP9 expression and activates ERK1/2, whereas knockdown of Gab2 inhibits MMP7 and MMP9 expression and reduces ERK1/2 activation.
b and c The levels of phosphor‑AKT, phosphor‑ERK1/2, MMP7 and MMP9 were calculated. The data are representative of at least three different
experiments ± SEM. *P < 0.05
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molecules essential for both ovarian cancer and melanoma
[12, 13]. Similarly, another study indicated that the level
of Gab2 expression was significantly associated with
metastatic progression of breast cancer [31]. Moreover,
efficient ErbB2-driven mammary tumorigenesis and
metastatic spread requires Gab2 expression [32]. Our
results shed new light on the role of Gab2 in the pro-
motion of cancer metastasis.
It has been reported that Gab2 regulates cytoskeletal
organization and migration of mammary epithelial cells by
modulating RhoA activation [33]. Interestingly, a recent
study has shown that miR125a-5p could inhibit migration
and invasion of glioma cells by mediating Gab2 to affect
cytoskeleton rearrangement and MMPs expression [34].
These studies suggest that Gab2 might promote cancer
metastasis by regulating the EMT. In this study, we dem-
onstrated that upregulation of Gab2 expression induced
the conversion of polarized epithelial cells to spindle-
shaped, fibroblast-like mesenchymal cells with decreased
cell-cell contact, enhanced invasion and migration in CRC
cells, upregulated vimentin, MMP7 and MMP9 and down-
regulated E-cadherin. These findings provided new evi-
dence supporting the involvement of Gab2 in driving
cancer cells metastasis through the regulation of EMT.
Of further interest, we examined the possible pathway
of Gab2 participating in cell metastasis of colorectal car-
cinoma and found that increased ERK1/2 phosphorylation
in Gab2-upregulated CRC cells. Unfortunately, we did not
detect any significant association between AKT phosphor-
ylation and the expression of Gab2 in CRC cells. In
addition, pharmacological inhibitor of MEK could reverse
the effects of Gab2 on CRC cells migration and invasion,
and partially restore E-cadherin expression, suggesting
that Gab2-induced EMT is dependent on MEK/ERK sig-
naling in CRC. Notably, activating genetic mutations in
the PI3K/AKT and the MEK/ERK pathways have been im-
plicated in CRC. Gab2 has been recognized as critical acti-
vators of the PI3K/AKT and/or the SHP2/ERK pathways
in several cellular systems [10]. In theory, the level of
Gab2 should affect AKT and ERK phosphorylation in
CRC cells. However, SW620 cells transformed by down-
regulation of Gab2 did not show marked reduction of
AKT phosphorylation in comparison with control cells.
Similarly, at higher concentration ratios of PI3K/SHP2 in
VEGF-stimulated endothelial cells, the lipid kinase is not
limiting and AKT is phosphorylated to the same extent re-
gardless of Gab2 knockdown, indicated that sufficient
PI3K is activated for maximal AKT phosphorylation [35].
Fig. 6 Inhibitor of MEK reduces Gab2-induced EMT, cell migration and invasion. a SW480-Gab2 cells were treated or not with 20 μM U0126 during
16 h after which proteins were analyzed by western blot with specific antibodies against E-cadherin, vimentin, MMP7, MMP9, phosphorylated ERK1/2
and total ERK1/2. b and c SW480-Gab2 cells were subjected to transwell migration and invasion assays in the absence (vehicle), or presence of 20 μM
U0126. ***P < 0.001
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One plausible explanation is that the expression of Gab2
cannot markedly affect the concentration ratios of PI3K in
these cells. Additionally, other Gab2-mediated oncogenic
pathways need to be analyzed in order to clearly deter-
mine whether there is a link between Gab2 expression
and EMT startup.
In summary, our study demonstrates that Gab2 could
induce EMT and promote CRC cell metastasis through
the MEK/ERK/MMP signaling. However, further studies
are needed to pinpoint the target gene of Gab2, which can
act as Gab2 promoters/suppressors regulated CRC metas-
tasis. The present study provides a novel fundamental
insight into how Gab2 promotes metastasis in colorectal
carcinoma.
Conclusions
Our study provides a better understanding on both the
molecular mechanism and functional role of Gab2 in hu-
man CRC. Our current work revealed that Gab2 exerted
its role as oncogene in CRC by facilitating cancer cell mi-
gration and invasion. Notably, Gab2 can upregulate MMP7
and MMP9 expression via MEK/ERK signaling pathway in
CRC. Our study identified that Gab2 is a novel regulator of
EMT through Gab2-medated MEK/ERK/MMP signaling,
indicating its potential therapeutic value for reducing CRC
metastasis.
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